While Imfinzi showed some benefit in specific subgroups, it did not significantly improve overall disease-free survival for patients with NSCLC. The study found that patients with higher levels of ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading ...

Imfinzi Improves Outcomes Mooradian and colleagues analyzed data from patients with unresectable stage 3 NSCLC who were treated with chemoradiotherapy: 332 received Imfinzi after chemoradiotherapy, ...

Using Imfinzi before and after surgery pared down the risk of disease recurrence, progression or death by 32% in patients with resectable stage 2 to 3b NSCLC, according to the AEGEAN data ...

A phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­—small cell lung cancer (NSCLC) who did not have disease progression after concurrent ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading ...

While the company said the data for Imfinzi monotherapy warranted further subgroup analysis, the results of MYSTIC greatly diminish the potential for Imfinzi to compete against the only checkpoint ...

AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival in early-stage NSCLC. Despite this, Imfinzi's safety profile remains consistent.

AstraZeneca (NASDAQ:AZN) said Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival (PFS) in advanced endometrial cancer when added to chemotherapy in a ...

Imfinzi is also being tested in a separate late stage study in certain patients with a form of lung cancer for which data is expected in 2021, AstraZeneca said.

Imfinzi, when combined with chemotherapy, resulted in a median 13 months survival in a late-stage small cell lung cancer trial, the British drugmaker said on Monday, adding trial details to a ...